MARKET

ARRY

Array Biopharma
ARRY
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-64.4618
42.87
35.15
10,610,774,009.55
About ARRY
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
More

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Array Biopharma stock information, including NASDAQ:ARRY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARRY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARRY stock methods without spending real money on the virtual paper trading platform.